Longboard Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Financial Statements

In millions of USD, except per-share amounts

	FY2023 1 months to Jan 31, 2024	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Depreciation and amortization
(Accretion) amortization of premiums on investments, net
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Accounts payable
Accrued research and development expenses
Accrued compensation and related expenses
Accrued other expenses
Operating right-of-use assets and lease liabilities, net
Net cash used in operating activities
Cash flows from investing activities:
Purchases of short-term investments
Maturities of short-term investments
Purchase of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Series A convertible preferred stock financing costs
Proceeds from initial public offering
Initial public offering costs
Financing related fees
Proceeds from issuance of common stock
Payments for offering costs
Proceeds from exercise of stock options
Net cash provided by (used in) financing activities
Net increase in cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the period
Cash and cash equivalents at the end of the period
Common stock issued on conversion of convertible preferred stock in connection with initial public offering

Comments